Base de dados : LILACS
Pesquisa : D12.644.360.325.150.750 [Categoria DeCS]
Referências encontradas : 2 [refinar]
Mostrando: 1 .. 2   no formato [Detalhado]

página 1 de 1

  1 / 2 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-950890
Autor: Madrigal, Alma; Tan, Lun; Zhao, Yuanxiang.
Título: Expression regulation and functional analysis of RGS2 and RGS4 in adipogenic and osteogenic differentiation of human mesenchymal stem cells
Fonte: Biol. Res;50:43, 2017. tab, graf.
Idioma: en.
Projeto: NIH; . NIH MBRS-RISE.
Resumo: BACKGROUND: Understanding the molecular basis underlying the formation of bone-forming osteocytes and lipid-storing adipocytes will help provide insights into the cause of disorders originating in stem/progenitor cells and develop therapeutic treatments for bone- or adipose-related diseases. In this study, the role of RGS2 and RGS4, two members of the regulators of G protein signaling (RGS) family, was investigated during adipogenenic and osteogenenic differentiation of human mesenchymal stem cells (hMSCs). RESULTS: Expression of RGS2 and RGS4 were found to be inversely regulated during adipogenesis induced by dexamethasone (DEX) and 3-isobutyl-methylxanthine, regardless if insulin was present, with RGS2 up-regulated and RGS4 down-regulated in response to adipogenic induction. RGS2 expression was also up-regulated during osteogenesis at a level similar to that induced by treatment of DEX alone, a shared component of adipogenic and osteogenic differentiation inducing media, but significantly lower than the level induced by adipogenic inducing media. RGS4 expression was down-regulated during the first 48 h of osteogenesis but up-regulated afterwards, in both cases at levels similar to that induced by DEX alone. Expression knock-down using small interfering RNA against RGS2 resulted in decreased differentiation efficiency during both adipogenesis and osteogenesis. On the other hand, expression knock-down of RGS4 also resulted in decreased adipogenic differentiation but increased osteogenic differentiation. CONCLUSIONS: RGS2 and RGS4 are differentially regulated during adipogenic and osteogenic differentiation of hMSCs. In addition, both RGS2 and RGS4 play positive roles during adipogenesis but opposing roles during osteogenesis, with RGS2 as a positive regulator and RGS4 as a negative regulator. These results imply that members of RGS proteins may play multifaceted roles during human adipogenesis and osteogenesis to balance or counterbalance each other's function during those processes.
Descritores: Osteócitos/citologia
Osteogênese/fisiologia
Regulação da Expressão Gênica/fisiologia
Proteínas RGS/metabolismo
Adipogenia/fisiologia
Células-Tronco Mesenquimais/citologia
-Osteogênese/genética
Fatores de Tempo
Regulação da Expressão Gênica/genética
Proteínas RGS/genética
Adipogenia/genética
Limites: Humanos
Responsável: CL1.1 - Biblioteca Central


  2 / 2 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-679208
Autor: Brazilian Journal of Medical and Biological Research; Yin, Wanzhong; Wang, Ping; Wang, Xin; Song, Wenzhi; Cui, Xiangyan; Yu, Hong; Zhu, Wei.
Título: Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;46(6):546-554, 02/jul. 2013. tab, graf.
Idioma: en.
Resumo: Multidrug resistance (MDR) poses a serious impediment to the success of chemotherapy for laryngeal cancer. To identify microRNAs and mRNAs associated with MDR of human laryngeal cancer Hep-2 cells, we developed a multidrug-resistant human laryngeal cancer subline, designated Hep-2/v, by exposing Hep-2 cells to stepwise increasing concentrations of vincristine (0.02-0.96'µM). Microarray assays were performed to compare the microRNA and mRNA expression profiles of Hep-2 and Hep-2/v cells. Compared to Hep-2 cells, Hep-2/v cells were more resistant to chemotherapy drugs (∼45-fold more resistant to vincristine, 5.1-fold more resistant to cisplatin, and 5.6-fold more resistant to 5-fluorouracil) and had a longer doubling time (42.33±1.76 vs 28.75±1.12'h, P<0.05), higher percentage of cells in G0/G1 phase (80.98±0.52 vs 69.14±0.89, P<0.05), increased efflux of rhodamine 123 (95.97±0.56 vs 12.40±0.44%, P<0.01), and up-regulated MDR1 expression. A total of 7 microRNAs and 605 mRNAs were differentially expressed between the two cell types. Of the differentially expressed mRNAs identified, regulator of G-protein signaling 10, high-temperature requirement protein A1, and nuclear protein 1 were found to be the putative targets of the differentially expressed microRNAs identified. These findings may open a new avenue for clarifying the mechanisms responsible for MDR in laryngeal cancer.
Descritores: Resistencia a Medicamentos Antineoplásicos/genética
Neoplasias Laríngeas/genética
MicroRNAs/isolamento & purificação
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética
RNA Mensageiro/isolamento & purificação
-Antineoplásicos/farmacologia
Fatores de Transcrição Hélice-Alça-Hélice Básicos/genética
Linhagem Celular Tumoral
Proliferação de Células/efeitos dos fármacos
Cisplatino/farmacologia
Citometria de Fluxo
Fluoruracila/farmacologia
Pontos de Checagem da Fase G1 do Ciclo Celular
Genes MDR
Neoplasias Laríngeas/tratamento farmacológico
Proteínas de Neoplasias/genética
Reação em Cadeia da Polimerase em Tempo Real
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Proteínas RGS/genética
/farmacocinética
RHODAMINE ACETYLENE/farmacocinética
Serina Endopeptidases/genética
Análise Serial de Tecidos
Vincristina/farmacologia
Limites: Humanos
Responsável: BR1.1 - BIREME



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde